UNION CITY, Calif., April 20, 2018 /PRNewswire/ -- Abaxis, Inc. (Nasdaq: ABAX), a global diagnostics company manufacturingpoint-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2018, ended March
Participants can dial (844) 855-9498 or (412) 317-5496 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company's website at www.abaxis.com. A replay of the call is available by visiting www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10119767, through May 3, 2018.
About AbaxisAbaxis, Inc. is a worldwide developer, manufacturer and marketer of portable blood analysis systems that are used in a broad range of medical specialties in human or veterinary patient care to provide clinicians with rapid blood constituent measurements. Our mission is to improve the efficiency of care delivery to and the quality of life of patients in the medical and veterinary markets. We provide leading edge technology and tools that support best medical practices, enabling physicians and veterinarians to respond to the health needs of their clients at the point of care while operating economical and profitable practices. For more information, visit http://www.abaxis.com
Contact: Clint Severson Lytham Partners, LLC Chief Executive Officer Joe Dorame, Joe Diaz & Robert Blum Abaxis, Inc. 602-889-9700 510-675-6500
View original content:http://www.prnewswire.com/news-releases/abaxis-to-report-fourth-quarter-and-fiscal-year-2018-financial-results-on-thursday-april-26-2018-300633536.html
SOURCE Abaxis, Inc.
Subscribe to our Free Newsletters!
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...
Fosnetupitant and Palonosetron (a fixed antiemetic combination) injection was approved by FDA in ...View All